Receptors, Thrombopoietin
"Receptors, Thrombopoietin" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Cell surface receptors that are specific for THROMBOPOIETIN. They contain two central FIBRONECTIN TYPE III DOMAINS and signal through interaction with JANUS KINASES such as JANUS KINASE 2.
| Descriptor ID |
D053628
|
| MeSH Number(s) |
D12.776.543.750.705.852.610
|
| Concept/Terms |
Receptors, Thrombopoietin- Receptors, Thrombopoietin
- Thrombopoietin Receptors
- CD110 Antigens
- MPL Ligand Receptor
- Thrombopoietin Receptor
- Antigens, CD110
|
Below are MeSH descriptors whose meaning is more general than "Receptors, Thrombopoietin".
Below are MeSH descriptors whose meaning is more specific than "Receptors, Thrombopoietin".
This graph shows the total number of publications written about "Receptors, Thrombopoietin" by people in this website by year, and whether "Receptors, Thrombopoietin" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 0 | 1 | 1 |
| 1999 | 0 | 2 | 2 |
| 2000 | 0 | 1 | 1 |
| 2002 | 0 | 1 | 1 |
| 2003 | 0 | 1 | 1 |
| 2004 | 0 | 1 | 1 |
| 2005 | 0 | 2 | 2 |
| 2008 | 1 | 1 | 2 |
| 2009 | 2 | 0 | 2 |
| 2010 | 4 | 0 | 4 |
| 2011 | 2 | 0 | 2 |
| 2012 | 0 | 2 | 2 |
| 2014 | 0 | 1 | 1 |
| 2015 | 1 | 3 | 4 |
| 2016 | 2 | 1 | 3 |
| 2017 | 1 | 2 | 3 |
| 2018 | 0 | 1 | 1 |
| 2019 | 0 | 3 | 3 |
| 2020 | 2 | 0 | 2 |
| 2021 | 1 | 1 | 2 |
| 2023 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Receptors, Thrombopoietin" by people in Profiles.
-
Genetic basis and molecular profiling in myeloproliferative neoplasms. Blood. 2023 04 20; 141(16):1909-1921.
-
Mutational landscape of blast phase myeloproliferative neoplasms (MPN-BP) and antecedent MPN. Int Rev Cell Mol Biol. 2022; 366:83-124.
-
The efficacy and safety of thrombopoietin receptor agonists in patients with chronic liver disease undergoing elective procedures: a systematic review and meta-analysis. Platelets. 2022 Jan 02; 33(1):66-72.
-
Protein quality control through endoplasmic reticulum-associated degradation maintains haematopoietic stem cell identity and niche interactions. Nat Cell Biol. 2020 10; 22(10):1162-1169.
-
Chronic myeloid neoplasms harboring concomitant mutations in myeloproliferative neoplasm driver genes (JAK2/MPL/CALR) and SF3B1. Mod Pathol. 2021 01; 34(1):20-31.
-
Concurrent JAK2 V617F and MPL W515L in myelodysplastic/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis. Leuk Lymphoma. 2020 04; 61(4):963-966.
-
Mutational profiling in myelofibrosis: implications for management. Int J Hematol. 2020 Feb; 111(2):192-199.
-
Targeting compensatory MEK/ERK activation increases JAK inhibitor efficacy in myeloproliferative neoplasms. J Clin Invest. 2019 03 04; 129(4):1596-1611.
-
Eltrombopag maintains human hematopoietic stem and progenitor cells under inflammatory conditions mediated by IFN-?. Blood. 2019 05 09; 133(19):2043-2055.
-
Eltrombopag for use in children with immune thrombocytopenia. Blood Adv. 2018 02 27; 2(4):454-461.